Effectiveness of Topical Tazarotene 0.1% Gel Versus Oral Fluconazole in Treatment    of Onychomycosis

Muhammad Ammar  Khan; Muhammad  Anjum; Laila  hassan; Saira  niazi; Safoora  Naveed; Umaima  Afzal

doi:10.51253/pafmj.v75i6.12720

Authors

Muhammad Ammar Khan Department of Dermatology, Pak-Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Anjum Department of Dermatology, Pak-Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Laila hassan Department of Dermatology, Pak-Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Saira niazi Department of Dermatology, Pak-Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Safoora Naveed Department of Dermatology, Pak-Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Umaima Afzal Department of Dermatology, Pak-Emirates Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i6.12720

Keywords:

Antifungal therapy, Fluconazole, Onychomycosis, Tazarotene, Treatment effectiveness

Abstract

Objective: The objective of this study was to assess the comparative effectiveness of topical Tazarotene 0.1% gel and weekly oral Fluconazole in the treatment of onychomycosis.

Study Design: Comparative prospective study.

Place and Duration of Study: Pak-Emirates Military Hospital, Rawalpindi, Pakistan, from July 2023 to Dec 2023.

Methodology: A total of 114 patients fulfilling the inclusion criteria were included in the research. A detailed history, dermatological examination, dermoscopy, and calculation of the Onychomycosis Severity Index (OSI) were employed in each patient to record the severity of their disease. The patients were randomized into two groups, i.e., Group-A, where twice daily application of topical Tazarotene 0.1% gel was applied for three months, and Group-B, where weekly oral Fluconazole tablet of 150mg was administered for three months. The Potassium Hydroxide mounts from nail material was performed at the end of treatment period in all the patients.

Results: Of the total, 53(46.5%) were male and 61(53.5%) were female. Following the comparison between two groups, a statistically significant difference was observed, suggesting that treatment with weekly oral Fluconazole (Group-B) had higher effectiveness and better treatment success compared to topical Tazarotene 0.1% gel (Group-A) in terms of the fall in the degree of OSI, dermoscopic findings, clinical evaluation, and potassium hydroxide (KOH) mount after treatment.

Conclusions: The effectiveness of Oral weekly Fluconazole is significantly higher than topical Tazarotene 0.1% gel in onychomycosis.

Downloads

Download data is not yet available.

References

1. Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol 2020; 34(9): 1972-1990. https;//doi:10.1111/jdv.16394

2. Joyce A, Gupta AK, Koenig L, Wolcott R, Carviel J. Fungal diversity and onychomycosis: An analysis of 8,816 toenail samples using quantitative PCR and next-generation sequencing. J Am Podiatr Med Assoc 2019; 109(1): 57-63.

https://doi:10.7547/17-070

3. Leung AK, Lam JM, Leong KF, Hon KL, Barankin B, Leung AA, et al. Onychomycosis: an updated review. Recent Adv. Inflamm. Allergy Drug Discov 2020; 14(1): 32-45.

https;//doi:10.2174/1872213X13666191026090713

4. Pang SM, Pang JYY, Fook-Chong S, Tan AL. Tinea unguium onychomycosis caused by dermatophytes: A ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. Singapore Med J 2018; 59(10): 524-527.

https;//doi:10.11622/smedj.2018037

5. Bombace F, Iovene MR, Galdiero M, Martora F, Nicoletti GF, D'Andrea M, et al. Non-dermatophytic onychomycosis diagnostic criteria: an unresolved question. Mycoses 2016; 59(9): 558-565. https://doi:10.1111/myc.12504

6. Gupta AK, Wang T, Cooper EA, Summerbell RC, Piguet V, Tosti A, et al. A comprehensive review of nondermatophyte mould onychomycosis: Epidemiology, diagnosis, and management. J Eur Acad Dermatol Venereol 2024; 38(3): 480-495.

https://doi:10.1111/jdv.19644

7. Subramanya SH, Subedi S, Metok Y, Kumar A, Prakash PY, Nayak N. Distal and lateral subungual onychomycosis of the fingernail in a neonate: A rare case. BMC Pediatr 2019; 19(1): 168. https://doi:10.1186/s12887-019-1549-9

8. Christenson JK, Peterson GM, Naunton M, Bushell M, Kosari S, Baby KE, et al. Challenges and opportunities in the management of onychomycosis. J Fungi 2018; 4(3): 87.

https://doi:10.3390/jof4030087

9. Angelo T, Borgheti-Cardoso LN, Gelfuso GM, Taveira SF, Gratieri T. Chemical and physical strategies in onychomycosis topical treatment: A review. Med Mycol 2017; 55(5): 461-475.

https://doi:10.1093/mmy/myw084

10. Houšť J, Spížek J, Havlíček V. Antifungal Drugs. Metabolites 2020; 10(3): 106. https://doi:10.3390/metabo10030106

11. Rana M, Altaf F, Bashir B, Rani Z. Frequency of associated factors of onychomycosis. J Pak Assoc Dermatol 2018; 27(3): 226-231.

12. Carney C, Tosti A, Daniel R, Scher R, Rich P, DeCoster J, et al. A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index. Arch Dermatol 2011; 147(11): 1277-1282.

https://doi:10.1001/archdermatol.2011.267

13. El-Salam SSA, Omar GA, Mahmoud MT, Said M. Comparative study between the effect of topical Tazarotene 0.1 gel alone vs its combination with tioconazole nail paint in treatment of onychomycosis. Dermatologic Therapy 2020; 33(6): e14333.

https://doi:10.1111/ dth.14333

14. Cosio T, Gaziano R, Zuccari G, Costanza G, Grelli S, Di Francesco P et al. Retinoids in Fungal Infections: From Bench to Bedside. Pharmaceuticals 2021; 14(10): 962.

https://doi:10.3390/ph14100962

15. Campione E, Paternò EJ, Costanza G, Diluvio L, Carboni I, Marino D, et al. Tazarotene as an alternative topical treatment for onychomycosis. Drug Des Devel Ther 2015; 9: 879-886.

https://doi:10.2147/DDDT.S69946

16. Aslam H, Muhammad SS, Saeed A, A M, Ghafar R, Abushehab S, et al. Comparison of Efficacy of the Combination of Topical Tazarotene Gel and Oral Fluconazole Versus Oral Fluconazole Monotherapy in the Treatment of Onychomycosis. Cureus 2025; 17(1): e78265. https://doi:10.7759/cureus.78265

17. Falotico JM, Lipner SR. Updated Perspectives on the Diagnosis and Management of Onychomycosis. Clin Cosmet Investig Dermatol 2022; 15: 1933-1957.

https://doi:10.2147/CCID.S362635

18. Axler E, Lipner SR. Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes. Infect Drug Resist 2024; 17: 819-843.

https://doi:10.2147/IDR.S431526

19. Usman B, Rehman A, Naz I, Anees M. Prevalence and antifungal drug resistance of dermatophytes in the clinical samples from Pakistan. Acta Microbiol Immunol Hung 2021; 68(4): 291-296.

https://doi:10.1556/030.2021.01461

20. Nickles MA, Lio PA, Mervak JE. Complementary and Alternative Therapies for Onychomycosis: A Systematic Review of the Clinical Evidence. Skin Appendage Disord 2022; 8(4): 269-279. https://doi:10.1159/000521703

21. Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Antifungal Drugs TDM: Trends and Update. Ther Drug Monit 2022; 44(1): 166-197.

https://doi:10.1097/FTD.0000000000000952